Lymphoma (cutaneous T-cell, mycosis fungoides, Sezary syndrome) - mogamulizumab [ID1405]
This appeal hearing will hear appeals against the Final Appraisal Document for the above technology submitted by the following organisations:
- Kyowa Kirin
- Lymphoma Action and Leukaemia Care
- UK Cutaneous Lymphoma Group
NICE also received an appeal from the British Association of Dermatologists, however this appeal was rejected during the scrutiny stage, which considers whether the appeal is valid under the two grounds of appeal.
The appeal panel will convene on Monday 10 May 2021 from 10am on Zoom, to hear oral representation from the appellants.
This page was last updated: